Clarus Therapeutics Holdings, Inc. Warrants
CRXTW
CRXTW was delisted on the 30th of August, 2022.
12 hedge funds and large institutions have $3.12M invested in Clarus Therapeutics Holdings, Inc. Warrants in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$320K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$220K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$187K |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$180K |
| 5 |
LA
Linden Advisors
New York
|
+$105K |
Top Sellers
CRXTW Hedge Fund Activity: Q1 2021 in Review
12 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q1 2021, worth a combined $3.12M.
Buyers outnumbered sellers: 12 funds opened new CRXTW positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $320K.
- 12 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $3.12M of Clarus Therapeutics Holdings, Inc. Warrants stock for Q1 2021.
- 12 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q1 2021 and 0 closed out, a net change of +12 holders.
- The largest Clarus Therapeutics Holdings, Inc. Warrants buyer in Q1 2021 was CVI Holdings, an estimated $320K added.
Based on aggregated 13F filings for Q1 2021.